Qiagen, Inovio to develop CDx

Create PDF

August 2019—Qiagen and Inovio Pharmaceuticals will collaborate to co-develop a companion diagnostic to guide clinical decision-making for the use of Inovio’s DNA-based immunotherapy to treat cervical dysplasia caused by human papillomavirus. The partnership focuses on Inovio’s VGX-3100, which is under investigation for the treatment of infection with HPV 16 and HPV 18 and precancerous lesions of the cervix (phase 3) and the vulva and anus (phase 2). VGX-3100 utilizes the patient’s own immune system to clear the HPV 16 and HPV 18 infections and precancerous lesions without the increased risks of surgery.

Inovio aims to make regulatory submissions for VGX-3100 in 2021.